TABLE 3.
Expt | Immunizationa
|
Effector CTL frequencyb
|
|||
---|---|---|---|---|---|
Primary | Secondary | LLO 91–99 | p60 217–225 | p60 449–457 | |
A | |||||
Wild type | 1/21,840 | 1/90,800 | 1/226,000 | ||
Wild type | Wild type | 1/2,350 | 1/5,600 | 1/19,000 | |
p60 218F | Wild type | 1/3,300 | 1/81,310 | 1/23,070 | |
B | |||||
Wild type | 1/31,500 | 1/99,050 | NDc | ||
92F | Wild type | 1/32,900 | 1/62,460 | ND | |
C | |||||
Wild type | 1/19,375 | 1/68,444 | ND | ||
92F | Wild type | 1/57,930 | 1/25,010 | ND |
BALB/c mice were immunized with the indicated strains, and 2 months later, they were injected with wild-type L. monocytogenes. Control animals were immunized with the wild-type strain at this time. Six days later, spleen cells were stimulated in culture, and the recovered cells were assessed for peptide-specific effector CTLs.
51Cr-labeled RMAS-Kd cells were pulsed with a 10−9 M concentration of the indicated peptide for 60 min, and then they were added at 5 × 103 cells/well. Serial dilutions of effector cells were added, and 4 to 6 h later, supernatant was collected for assay of 51Cr release. CTL frequency was determined as previously described (7). The data are representative of three experiments.
ND, not determined.